Lanthanide Nanotheranostics in Radiotherapy
International Journal of Molecular Sciences · 31.12.2025 · 27 (1) · 426
DOI: 10.3390/ijms27010426 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.12.2025. Verfasst von Shaofeng Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Energy Power and Mechanical Engineering, North China Electric Power University, Beijing 102206, China. Hauptthemen laut MEDLINE: Lanthanoid Series Elements, Theranostic Nanomedicine, Neoplasms, Radiation-Sensitizing Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 246 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, National College Students Innovation and Entrepreneurship Training Program.
Abstract (Originalsprache)
Radiotherapy, a cornerstone of cancer treatment, is critically limited by tumor radioresistance and off-target toxicity. Lanthanide-based nanomaterials (Ln-NPs) have recently emerged as a versatile and promising class of theranostic radiosensitizers to overcome these hurdles. This review comprehensively outlines the state-of-the-art in Ln-NP-enabled radiotherapy, beginning with their fundamental physicochemical properties and synthesis and then delving into the multi-level mechanisms of radiosensitization, including high-Z element-mediated physical dose amplification, catalytic generation of reactive oxygen species (ROS), and disruption of DNA damage repair pathways. The unique capacity of certain Ln-NPs to serve as MRI contrast agents is highlighted as the foundation for image-guided, dose-painting radiotherapy. We critically summarize the preclinical and clinical progress of representative systems, benchmarking them against other high-Z nanomaterials. Finally, this work discusses the ongoing challenges, such as biocompatibility, targeted delivery, and regulatory hurdles, and envisages future directions, including combinatorial strategies with immunotherapy and the development of personalized nanotheranostic paradigms. Through this synthesis, this review aims to provide a clear roadmap for the continued development and clinical integration of lanthanide nanotheranostics in oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Energy Power and Mechanical Engineering, North China Electric Power University, Beijing 102206, China.
- College of Science, Northeast Forestry University, Harbin 150040, China.
- College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
ORCID-Profile: Shaofeng Han, Yurun Liu
Förderung
- Fundamental Research Funds for the Central Universities
- National College Students Innovation and Entrepreneurship Training Program
Zitieren
APA
Han, S., Liu, Y., Cai, T., Liu, Y., & Ge-Zhang, S. (2025). Lanthanide Nanotheranostics in Radiotherapy. International Journal of Molecular Sciences, 27(1), 426. https://doi.org/10.3390/ijms27010426
Vancouver
Han S, Liu Y, Cai T, Liu Y, Ge-Zhang S. Lanthanide Nanotheranostics in Radiotherapy. International Journal of Molecular Sciences. 2025;27(1):426. doi:10.3390/ijms27010426
BibTeX
@article{Han2025,
author = {Han, Shaofeng and Liu, Yurun and Cai, Taoyang and Liu, Yanru and Ge-Zhang, Shangjie},
title = {Lanthanide Nanotheranostics in Radiotherapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {27},
number = {1},
pages = {426},
doi = {10.3390/ijms27010426}
}
EUVIMED